Reverse Transcriptase News and Research

RSS

Tenofovir gel safe for daily use over an extended period

A vaginal microbicide that incorporates an antiretroviral (ARV) drug normally used to treat people with HIV is safe for sexually active HIV-negative women to use every day over an extended period, suggest results of a clinical trial of tenofovir topical gel.

27 Feb 2008

Experimental anti-HIV gel is safe for women to use on a daily basis

An experimental anti-HIV gel is safe for women to use on a daily basis, according to researchers at the University of Alabama at Birmingham (UAB) and the University of Pittsburgh School of Medicine.

26 Feb 2008

Invitrogen and Agilent Technologies resolve all pending patent litigations

Invitrogen Corporation and Agilent Technologies have jointly announced a confidential settlement of multiple patent litigations pending between the two companies.

5 Feb 2008

New anti-HIV medication etravirine shows great promise

The AIDS Institute, a national public policy research, advocacy, and education organization, is encouraged with the FDA's approval of the first new non-nucleoside reverse transcriptase inhibitor (NNRTI) in nearly a decade.

4 Feb 2008

Improved diagnosis of cutaneous leishmaniasis thanks to new techniques

Cutaneous leishmaniasis (CL) is a non-lethal disease but can have grave consequences for the patient.

25 Jan 2008

AIDS Healthcare Foundation criticizes Etravirine's pricing

AIDS Healthcare Foundation (AHF) has urged Tibotec Pharmaceuticals Ltd., a division of Johnson & Johnson, to reconsider and reduce its steep price for its newest AIDS drug, etravirine (TMC 125), a non-nucleoside reverse transcriptase inhibitor, (NNRTI), which received Food and Drug Administration (FDA) approval on Friday after a fast track or 'priority review' and approval process granted to companies for medications and therapies intended to treat life-threatening illnesses such as AIDS.

22 Jan 2008

FDA approves etravirine tablets for HIV

The U.S. Food and Drug Administration has approved etravirine tablets for the treatment of HIV infection in adults who have failed treatment with other antiretrovirals.

21 Jan 2008

New HIV drug will help millions

Statistics released by the World Health Organisation (WHO) indicate that as many as 33 million people worldwide are currently living with the HIV virus which also killed 2 million people in 2007.

20 Jan 2008

New virus drug will have to shoot at moving targets

The reproduction of

22 Oct 2007

New biosensor detects avian influenza in just minutes

Quick identification of avian influenza infection in poultry is critical to controlling outbreaks, but current detection methods can require several days to produce results.

27 Sep 2007

Ardea Biosciences completes phase 1 trials of HIV drug RDEA806

Ardea Biosciences, Inc. has announced that it has successfully completed Phase 1 single-ascending-dose, multiple-ascending-dose, food-effect, and drug-interaction studies of RDEA806, a novel HIV non-nucleoside reverse transcriptase inhibitor (NNRTI), in healthy volunteers.

5 Sep 2007

Tibotec Pharmaceuticals submits NDA for investigational HIV treatment

Tibotec Pharmaceuticals Ltd. has announced the submission of a New Drug Application to the U.S. Food and Drug Administration (FDA) for TMC125 (etravirine), an investigational non- nucleoside reverse transcriptase inhibitor (NNRTI), being studied for use with other antiretroviral (ARV) agents as a treatment for people infected with HIV- 1.

19 Jul 2007

Etravirine reduces HIV viral loads when taken with Prezista

The experimental antiretroviral drug etravirine, made by Johnson & Johnson subsidiary Tibotec Pharmaceuticals, greatly reduces HIV viral loads in people with a history of drug resistance when taken in combination with Tibotec's antiretroviral Prezista, according to two studies published Saturday in the journal The Lancet.

10 Jul 2007

Etravirine effective for HIV supression

Treatment with TMC125 (etravirine) leads to better virological suppression than placebo as part of antiretroviral therapy in patients with documented resistance to non-nucleoside reverse transcriptase inhibitors (NNRTIs), conclude two randomised trials in this week's issue of The Lancet.

8 Jul 2007

Entecavir can compromise HIV treatment

Treating hepatitis B patients with the drug entecavir can cause those who are also infected with HIV to become resistant to two of the most important drugs in the anti-HIV arsenal, according to a new report in the New England Journal of Medicine.

23 Jun 2007

Drug warning prompts treatment changes for those infected with hepatitis B and HIV

Cross-resistance alarms raised earlier this year by Johns Hopkins researchers about a widely used antiviral therapy for hepatitis B liver infections have prompted swift treatment revisions by the drug's maker and governmental agencies.

23 Jun 2007

Major breakthrough for people with AIDS is on the horizon

Three new drugs are predicted to help transform the long-term prognosis for people with the AIDS virus, says an editorial in the journal, which points towards highly promising results from trials of three new drugs.

1 Jun 2007

Flash-heating breast milk infected with HIV successfully deactivates virus

A simple method of flash-heating breast milk infected with HIV successfully inactivated the free-floating virus, according to a new study led by researchers at the Berkeley and Davis campuses of the University of California.

22 May 2007

Drg resistant HIV quickly hides in infants' cells

New evidence shows that drug-resistant virus passed from mother-to-child can quickly establish itself in infants, CD4+ T cells where it can hide for years, likely limiting their options for future treatment.

1 May 2007

Decoy receptor 3 expressed in rheumatic synovial fibroblasts protects the cells against Fas-induced apoptosis

A complex autoimmune disease, rheumatoid arthritis (RA) is characterized by chronic inflammation and progressive joint damage. This process begins with hyperplasia, or excessive increase in size and thickness, of synovial tissue. Along with provoking cartilage and bone destruction, this abnormal tissue growth is resistant to apoptosis, the natural cell death vital to the generation of healthy new cells.

30 Mar 2007